Venture Capital Archives - Page 3 of 109 - Boston Life Sciences Times

Alnylam to Invest $250 Million to Expand U.S. Manufacturing With Enzymatic Ligation Platform

December 17, 2025

Revvity Introduces Signals Xynthetica AI Platform for Molecular and Materials Discovery

December 16, 2025

Capital Discipline Matters: Sam Zell’s Lessons for Every Entrepreneur

December 13, 2025

THIS WEEK'S STORIES

nChroma Bio Receives Clinical Trial Authorization to Launch First-in-Human Study of CRMA-1001 for Chronic Hepatitis B

December 16, 2025

Mobile Heartbeat Announces New Voice Enhancements and Resiliency Features for Clinical Communication Platform

December 17, 2025

Revvity Introduces Signals Xynthetica AI Platform for Molecular and Materials Discovery

December 16, 2025

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Venture Capital

Manifold Raises $18 Million Series B to Expand Vertical AI Platform for Life Sciences

Orum Therapeutics Raises Approximately $100 Million to Advance Degrader Antibody Conjugate Programs

Syremis Therapeutics Launches With $165 Million Series A to Advance New Treatments for Mental Health Disorders

Neurable Raises $35 Million Series A to Expand Everyday Brain-Computer Interface Technology

Cosette Pharmaceuticals Terminates Agreement to Acquire Mayne Pharma

Most Read

Manifold Raises $18 Million Series B to Expand Vertical AI Platform for Life Sciences

PureTech Appoints Robert Lyne as Chief Executive Officer

Orum Therapeutics Raises Approximately $100 Million to Advance Degrader Antibody Conjugate Programs

Syremis Therapeutics Launches With $165 Million Series A to Advance New Treatments for Mental Health Disorders

EDITOR PICKS

Alnylam to Invest $250 Million to Expand U.S. Manufacturing With Enzymatic Ligation Platform

Revvity Introduces Signals Xynthetica AI Platform for Molecular and Materials Discovery

Capital Discipline Matters: Sam Zell’s Lessons for Every Entrepreneur

THIS WEEK'S STORIES

nChroma Bio Receives Clinical Trial Authorization to Launch First-in-Human Study of CRMA-1001 for Chronic Hepatitis B

Mobile Heartbeat Announces New Voice Enhancements and Resiliency Features for Clinical Communication Platform

Revvity Introduces Signals Xynthetica AI Platform for Molecular and Materials Discovery

POPULAR CATEGORY

ABOUT US

FOLLOW US